Here are the 10-Q quarterly reports from Fortrea Holdings Inc. (FTRE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FTRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FTRE filings page.
Fortrea Holdings Inc. reported third-quarter revenue of $691.5 million, down 1.4% from $701.3 million a year earlier, and net income of $0.6 million versus a $15.9 million loss. Operating income was $15.0 million versus an $8.6 million loss. Nine-month revenue was $2,006.2 million versus $2,062.9 million, and net loss was $36.2 million; 2025 included $797.9 million of goodwill and other asset impairments.
Operating activities provided $72.7 million of cash in the nine months, versus $15.6 million used in 2025; cash and cash equivalents were $220.6 million at September 30, 2026. Backlog was $7.3 billion at that date after an approximately $558 million reduction for cumulative estimated changes in contract scope and study delivery requirements. Fortrea said the adjustment was not expected to materially affect near-term revenue expectations.
On October 19, 2026, Fortrea acquired Worldwide Clinical Trials’ Early Phase Services division for approximately $45.0 million, subject to customary purchase price adjustments. $41.0 million was payable at closing and $4.0 million as deferred consideration after completion, expiration or termination of certain transition services; approximately $39.0 million was paid in cash at closing, subject to further customary adjustments.
Fortrea Holdings (FTRE) filed its Q3 2025 10‑Q. Revenue rose to $701.3 million from $674.9 million a year ago, and the operating loss narrowed to $8.6 million. For the first nine months, revenue reached $2,062.9 million and net loss was $953.7 million, largely reflecting $797.9 million of goodwill impairments recorded in the first half.
Cash from operations for the nine months was $(15.6) million versus $245.7 million last year; cash ended at $131.3 million. The company sold $300.0 million of receivables under its securitization program and reported unearned revenue of $411.6 million, indicating contracted work in progress. Long‑term debt stood at $1,052.1 million, and Fortrea intends to repurchase up to $75.7 million of its 7.50% senior notes due 2030 pursuant to the asset sale covenant. Q3 segment operating income was $21.1 million.
Fortrea reports one segment (Clinical Services) and noted customer concentration, with one customer accounting for 19.8% of Q3 revenue. On June 11, 2025, the Board adopted a limited-duration stockholder rights plan.